BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$71.41 USD
+0.27 (0.38%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $71.42 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
BMRN 71.41 +0.27(0.38%)
Will BMRN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
Other News for BMRN
Biotech Alert: Searches spiking for these stocks today
BioMarin near-term impact from Ascendis data overblown, says Citi
Biotech Alert: Searches spiking for these stocks today
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO? (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
Hold Rating on BioMarin Pharmaceutical Amid Competitive Dynamics and Market Penetration Nuances for Voxzogo